Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Mallinckrodt
Healthtrust
McKinsey
Cerilliant
Fuji
Farmers Insurance
Chubb
Julphar

Generated: December 16, 2018

DrugPatentWatch Database Preview

Litigation Details for APOTEX, INC. v. CEPHALON, INC. (E.D. Pa. 2006)

« Back to Dashboard

APOTEX, INC. v. CEPHALON, INC. (E.D. Pa. 2006)

Docket ➤ Sign Up Date Filed 2006-06-26
Court District Court, E.D. Pennsylvania Date Terminated 2012-08-29
Cause 15:1 Antitrust Litigation Assigned To Mitchell S. Goldberg
Jury Demand None Referred To MAGISTRATE JUDGE DAVID R. STRA
Parties APOTEX, INC.; BARR LABORATORIES, INC.; CEPHALON, INC.; MYLAN LABORATORIES, INC.; RANBAXY LABORATORIES, LTD.; RANBAXY PHARMACEUTICALS, INC.; TEVA PHARMACEUTICAL INDUSTRIES, LTD.; TEVA PHARMACEUTICALS USA, INC.
Patents 5,010,010; 5,618,845; 7,297,346; RE37,516
Attorneys A. SIDNEY KATZ; AMY K. WIGMORE; ANTHONY S. VOLPE; BRETT ALAN KRATZ; BRIAN J. SODIKOFF; CHARLES J. BLOOM; CHRISTINE E. BESTOR; DANIEL M. ESRICK; DANIEL R. CHERRY; DANIELLE R. FOLEY; DAVID E. EDWARDS; DAVID G. ADAMS; DAVID J. CREAGAN; DAVID L. COMERFORD; EDWARD A. DIVER; EDWARD F. MANNINO; EDWIN JOHN U; FRANK R. EMMERICH , JR.; GREGORY L. SKIDMORE; GREGORY P. TERAN; HOWARD I. LANGER; J. DOUGLAS BALDRIDGE; JAMES C. BURLING; JEFFERY A. DAILEY; JEFFREY B. KORN; JEREMY C. DANIEL; JOHN A. GUERNSEY; JOHN J. O'MALLEY; JOSEPH E. WOLFSON; JULIE A. KATZ; KATHERINE M. KATCHEN; LISA JOSE FALES; MARK A. FORD; MARTIN S. MASAR; MATTHEW RYAN VARZALLY; MICHAEL A. KROL; MICHAEL E. SACKS; MICHAEL N. ONUFRAK; MICHELLE D. MILLER; MOLLY GEISSENHAINER; NANCY J. GELLMAN; NEIL J. HAMBURG; NEILL C. KLING; PAUL T. MCGURKIN , JR.; PETER A. SPAETH; PETER J. KOLOVOS; RICHARD W. MCLAREN , JR.; ROBERT B. BREISBLATT; ROBERT J. GUNTHER , JR.; SARAH B. PETTY; SARAH CHOI; STEVEN E. FELDMAN; VINCENT E. VERROCCHIO; WILLIAM H. ROONEY
Firms Brett Alan Kratz; Kirkland & Ellis LLP; Lewis Brisbois Bisgaard & Smith, LLP-PA; Neill C. Kling; Stevens & Lee Pc
Link to Docket External link to docket
Small Molecule Drugs cited in APOTEX, INC. v. CEPHALON, INC.
The small molecule drugs covered by the patents cited in this case are ➤ Sign Up and ➤ Sign Up .
Biologic Drugs cited in APOTEX, INC. v. CEPHALON, INC.
The biologic drug covered by the patents cited in this case is ➤ Sign Up .

Details for APOTEX, INC. v. CEPHALON, INC. (E.D. Pa. 2006)

Date Filed Document No. Description Snippet Link To Document
2017-05-19 1135 had [he] done a step function, five five five and then ten ten ten, [he is] pretty confident it wouldn’…that such patent has expired; (3) the date that such patent will expire; or (4) “that such patent is invalid… 3 reissue patent on modafinil, U.S. Patent No. RE 37,516 (“the RE ‘516 patent”), in 2002, which…and all patents covering the brand-name drug, certifying either: (1) that the relevant patent information…ANDA constitutes an act of patent infringement, often prompting the patent holder to file a lawsuit. External link to document
2017-05-31 1164 In 1997, Cephalon was issued U.S. Patent No. 5,618,845, covering specific formulations of modafinil…granted a reissue patent on modafinil, U.S. Patent No. RE 37,516 (“the RE ‘516 patent”) in 2002. Modafinil…Cephalon’s RE ‘516 patent was either invalid or the generic products did not infringe the patent. In 2003, Cephalon…evidence or argument relating to U.S. Patent No. 7,297,346 (the “’346 Patent”).5 According to Plaintiffs, in… ‘346 Patent because Defendants have successfully avoided discovery concerning the ‘346 Patent by agreeing External link to document
2010-03-29 223 Memorandum and/or Opinion 15, 2002, as a reissue patent for the 5 ,618,845 patent (hereinafter “‘845”), Which Cephalon surrendered…Cephalon’s RE‘516 patent The Generic Defendants each asserted patent invalidity, patent unenforceability…of a patent, one (1) court has noted that: Engrafted into patent law is the notion that a patent grant…profiting by the patented invention.” 'fhus, the Patent Act essentially provides the patent owner “With…RE‘S 16 patent because Cephalon knew prior to the underlying patent litigation that the patent was invalid External link to document
2010-10-07 335 Memorandum and/or Opinion Apotex Second Am. Comp., ¶¶ 39, 51, 147; U.S. Patent No. RE37,516 E (filed Apr. 1, 1999).) …original complaint, which raised patent claims regarding Cephalon’s RE‘516 patent for Provigil®1 and antitrust…does not infringe on Cephalon’s RE‘516 patent or the ‘346 patent. On July 16, 2010, the parties… respective positions. II. The Patent The RE‘516 patent covers a pharmaceutical composition…before Cephalon sought the RE‘516 patent and consequently, the RE‘516 patent could only be designed to cover External link to document
Date Filed Document No. Description Snippet Link To Document

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Daiichi Sankyo
Farmers Insurance
Chubb
US Department of Justice
Argus Health
Merck
Citi
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.